Anticoagulation During Pregnancy

ABSTRACT

Venous thromboembolism (VTE) occurs infrequently but is a leading cause of illness and death during pregnancy and the puerperium. In the general population the incidence of pregnancy-associated VTE is approximately 1 in 1500 deliveries. The risk of VTE is five times higher in a pregnant than in a nonpregnant woman. Postpartum the VTE risk is even higher. Women with congenital abnormalities or persistent presence of antiphospholipid antibodies have an increased risk of VTE during pregnancy and the puerperium. Women with previous VTE have an approximately 3.5-fold increased risk of recurrent VTE during pregnancy.

Heparin does not cross the placenta and is therefore the anticoagulant of choice. In case of acute thrombosis during pregnancy, treatment is performed in the same manner as for nonpregnant patients. There is an ongoing debate whether pregnant women with previous venous thrombosis should routinely receive prophylactic anticoagulation. Patients who have hereditary antithrombin deficiency, antiphospholipid antibodies, a combined abnormality, or a history of a severe thrombotic event (pulmonary embolism or extended deep vein thrombosis) should be advised to use prophylactic heparin during pregnancy, starting during the first trimester. Postpartum prophylaxis should be given to all women with an increased risk for VTE.

A large body of evidence has been presented that hypercoagulability may cause recurrent abortions, stillbirth, and preeclampsia. There is no doubt that the antiphospholipid syndrome is strongly associated with fetal loss. The combination of heparin and aspirin significantly decreases the fetal loss rate during pregnancy and thus this is the treatment of choice in this patient group. Several studies indicate that women with recurrent miscarriage may benefit from heparin administration during pregnancy, however, data from controlled trials have not yet been published. In women with artificial heart valves, maternal and fetal complications are frequent despite anticoagulation, but oral anticoagulants can reduce the risk for maternal complications.

KEYWORDS

Venous thromboembolism - pregnancy - heparin - prophylaxis - oral anticoagulants

REFERENCES

• 1 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton L J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med . 1998;  158 585-593
• 2 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study.  Lancet . 1995;  346 1575-1582
• 3 Letsky E A, De Swiet M. Thromboembolism in pregnancy and its management.  Br J Haematol . 1984;  57 543-552
• 4 Toglia M R, Weg J G. Venous thromboembolism during pregnancy.  N Engl J Med . 1996;  335 108-114
• 5 National Institutes of Health Consensus Development Conference. Prevention of venous thrombosis and pulmonary embolism.  JAMA . 1986;  256 744-749
• 6 Rosendaal F R. Risk factors for venous thrombotic disease.  Thromb Haemost . 1999;  82 610-619
• 7 Conard J, Horellou M H, van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women.  Thromb Haemost . 1990;  63 319-320
• 8 Pabinger I, Schneider B. for the Gesellschaft für Thrombose- und Haemostaseforschung (GTH) Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study.  Arterioscler Thromb Vasc Biol . 1996;  16 742-748
• 9 Gerhardt A, Scharf R E, Beckmann M W. et al . Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med . 2000;  342 374-380
• 10 McColl M D, Ramsay J E, Tait R C. et al . Risk factors for pregnancy associated venous thromboembolism.  Thromb Haemost . 1997;  78 1183-1188
• 11 Pabinger I, Nemes L, Rintelen C. et al . Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden.  Hematol J . 2000;  1 37-41
• 12 Bates S M, Ginsberg J S. How we manage venous thromboembolism during pregnancy.  Blood . 2002;  100 3470-3478
• 13 Iturbe-Alessio I, del Carmen Fonesca M, Mutchinik O. et al . Risks of anticoagulant therapy in pregnant women with artificial heart valves.  N Engl J Med . 1986;  315 1390-1393
• 14 Ginsberg J S, Hirsh J, Turner C D. et al . Risks to the fetus of anticoagulation therapy during pregnancy.  Thromb Haemost . 1989;  61 197-203
• 15 Sanson B J, Lensing A WA, Prins M H. et al . Safety of low-molecular-weight heparin in pregnancy: a systematic review.  Thromb Haemost . 1999;  81 668-672
• 16 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.  Thromb Haemost . 1994;  71 7-11
• 17 Pettila V, Leinonen P, Markkola A. et al . Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.  Thromb Haemost . 2002;  87 182-186
• 18 Melissari E, Parker C J, Wilson N V. et al . Use of low molecular weight heparin in pregnancy.  Thromb Haemost . 1992;  68 652-656
• 19 Lagrange F, Vergnes C, Brun J L. et al . Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra®) in the dually perfused human cotyledon in vitro.  Thromb Haemost . 2002;  87 831-835
• 20 Pabinger I, Grafenhofer H, Kyrle P A. et al . Temporary increase in the risk of recurrence during pregnancy in women with a history of venous thromboembolism.  Blood . 2002;  100 1060-1062
• 21 Tengborn L, Bergqvist D, Mätzsch T, Bergqvist A, Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?.  Am J Obstet Gynecol . 1989;  160 90-94
• 22 Brill-Edwards P, Ginsberg J S, Gent M. et al . Safety of withholding heparin in pregnant women with a history of venous thromboembolism.  N Engl J Med . 2000;  343 1439-1444
• 23 Grafenhofer H, Kaider A, Kyrle P A. et al . Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis (abstr).  Thromb Haemost . 2001;  86(Suppl) P1525
• 24 Ginsberg J S, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy.  Chest . 2001;  119 122S-131S
• 25 Preston F E, Rosendaal F R, Walker I D. et al . Increased fetal loss in women with heritable thrombophilia.  Lancet . 1996;  348 913-916
• 26 Kupferminc M J, Eldor A, Steinman N. et al . Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med . 1999;  40 9-13
• 27 Lindqvist P G, Svensson P J, Marsál K, Grennert L, Luterkort M, Dahlbäck B. Activated protein C resistance (FV:Q⁵⁰⁶) and pregnancy.  Thromb Haemost . 1999;  81 532-537
• 28 Rai R, Cohen H, Dave M, Regan L. Randomized controlled trial of aspirin plus heparin in pregnant women with recurring miscarriage associated with antiphospholipid antibodies.  BMJ . 1997;  314 253-257
• 29 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost . 2000;  83 693-697
• 30 Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.  J Thromb Haemost . 2003;  1 433-438
• 31 Chan W S, Anand S, Ginsberg J S. Anticoagulation of pregnant women with mechanical heart valves.  Arch Intern Med . 2000;  160 191-196
• 32 Vitale N, de Feo M, de Santo S L, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves.  J Am Coll Cardiol . 1999;  33 1637-1641